Literature DB >> 24327389

Racial/ethnic differences in clinical trial enrollment, refusal rates, ineligibility, and reasons for decline among patients at sites in the National Cancer Institute's Community Cancer Centers Program.

Aisha T Langford1, Ken Resnicow, Eileen P Dimond, Andrea M Denicoff, Diane St Germain, Worta McCaskill-Stevens, Rebecca A Enos, Angela Carrigan, Kathy Wilkinson, Ronald S Go.   

Abstract

BACKGROUND: This study examined racial/ethnic differences among patients in clinical trial (CT) enrollment, refusal rates, ineligibility, and desire to participate in research within the National Cancer Institute's Community Cancer Centers Program (NCCCP) Clinical Trial Screening and Accrual Log.
METHODS: Data from 4509 log entries were evaluated in this study. Four logistic regression models were run using physical/medical conditions, enrollment into a CT, patient eligible but declined a CT, and no desire to participate in research as dependent variables.
RESULTS: Age ≥ 65 years (OR = 1.51, 95% CI = 1.28-1.79), males (OR = 2.28, 95% CI = 1.92-2.71), and non-Hispanic black race (OR = 1.53, 95% CI = 1.2-1.96) were significantly associated with more physical/medical conditions. Age ≥ 65 years was significantly associated with lower CT enrollment (OR = 0.83, 95% CI = 0.7-0.98). Males (OR = 0.78, 95% CI = 0.65-0.94) and a higher grade level score for consent form readability (OR = 0.9, 95% CI = 0.83-0.97) were significantly associated with lower refusal rates. Consent page length ≥ 20 was significantly associated with lower odds of "no desire to participate in research" among CT decliners (OR = 0.75, 95% CI = 0.58-0.98).
CONCLUSIONS: There were no racial/ethnic differences in CT enrollment, refusal rates, or "no desire to participate in research" as the reason given for CT refusal. Higher odds of physical/medical conditions were associated with older age, males, and non-Hispanic blacks. Better management of physical/medical conditions before and during treatment may increase the pool of eligible patients for CTs. Future work should examine the role of comorbidities, sex, age, and consent form characteristics on CT participation.
© 2013 American Cancer Society.

Entities:  

Keywords:  African Americans; Hispanic; cancer; clinical trials; medical research; minorities; racial/ethnic

Mesh:

Year:  2013        PMID: 24327389      PMCID: PMC3947654          DOI: 10.1002/cncr.28483

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  16 in total

Review 1.  Barriers to recruiting underrepresented populations to cancer clinical trials: a systematic review.

Authors:  Jean G Ford; Mollie W Howerton; Gabriel Y Lai; Tiffany L Gary; Shari Bolen; M Chris Gibbons; Jon Tilburt; Charles Baffi; Teerath Peter Tanpitukpongse; Renee F Wilson; Neil R Powe; Eric B Bass
Journal:  Cancer       Date:  2008-01-15       Impact factor: 6.860

Review 2.  Never too old? Age should not be a barrier to enrollment in cancer clinical trials.

Authors:  Matti S Aapro; Claus-Henning Köhne; Harvey Jay Cohen; Martine Extermann
Journal:  Oncologist       Date:  2005-03

3.  Comorbidity and survival disparities among black and white patients with breast cancer.

Authors:  C Martin Tammemagi; David Nerenz; Christine Neslund-Dudas; Carolyn Feldkamp; David Nathanson
Journal:  JAMA       Date:  2005-10-12       Impact factor: 56.272

4.  Increasing minority participation in cancer clinical trials: the minority-based community clinical oncology program experience.

Authors:  Worta McCaskill-Stevens; Martha M McKinney; Cynthia G Whitman; Lori M Minasian
Journal:  J Clin Oncol       Date:  2005-08-01       Impact factor: 44.544

5.  Randomized, controlled trial of an easy-to-read informed consent statement for clinical trial participation: a study of the Eastern Cooperative Oncology Group.

Authors:  Cathy A Coyne; Ronghui Xu; Peter Raich; Kathy Plomer; Mark Dignan; Lari B Wenzel; Diane Fairclough; Thomas Habermann; Linda Schnell; Susan Quella; David Cella
Journal:  J Clin Oncol       Date:  2003-03-01       Impact factor: 44.544

6.  Analysis of Maryland cancer patient participation in National Cancer Institute-supported cancer treatment clinical trials.

Authors:  Claudia R Baquet; Gary L Ellison; Shiraz I Mishra
Journal:  J Health Care Poor Underserved       Date:  2009-05

7.  Use of the National Cancer Institute Community Cancer Centers Program screening and accrual log to address cancer clinical trial accrual.

Authors:  Diane St Germain; Andrea M Denicoff; Eileen P Dimond; Angela Carrigan; Rebecca A Enos; Maria M Gonzalez; Kathy Wilkinson; Michelle A Mathiason; Brenda Duggan; Shaun Einolf; Worta McCaskill-Stevens; Donna M Bryant; Michael A Thompson; Stephen S Grubbs; Ronald S Go
Journal:  J Oncol Pract       Date:  2014-01-14       Impact factor: 3.840

8.  Influence of clinical communication on patients' decision making on participation in clinical trials.

Authors:  Terrance L Albrecht; Susan S Eggly; Marci E J Gleason; Felicity W K Harper; Tanina S Foster; Amy M Peterson; Heather Orom; Louis A Penner; John C Ruckdeschel
Journal:  J Clin Oncol       Date:  2008-06-01       Impact factor: 44.544

9.  Participation in cancer clinical trials: race-, sex-, and age-based disparities.

Authors:  Vivek H Murthy; Harlan M Krumholz; Cary P Gross
Journal:  JAMA       Date:  2004-06-09       Impact factor: 56.272

Review 10.  Are racial and ethnic minorities less willing to participate in health research?

Authors:  David Wendler; Raynard Kington; Jennifer Madans; Gretchen Van Wye; Heidi Christ-Schmidt; Laura A Pratt; Otis W Brawley; Cary P Gross; Ezekiel Emanuel
Journal:  PLoS Med       Date:  2005-12-06       Impact factor: 11.069

View more
  46 in total

1.  Enrolling Minority and Underserved Populations in Cancer Clinical Research.

Authors:  Sherrie F Wallington; Chiranjeev Dash; Vanessa B Sheppard; Tawara D Goode; Bridget A Oppong; Everett E Dodson; Rhonda N Hamilton; Lucile L Adams-Campbell
Journal:  Am J Prev Med       Date:  2015-10-21       Impact factor: 5.043

2.  Assessing the readability of ClinicalTrials.gov.

Authors:  Danny T Y Wu; David A Hanauer; Qiaozhu Mei; Patricia M Clark; Lawrence C An; Joshua Proulx; Qing T Zeng; V G Vinod Vydiswaran; Kevyn Collins-Thompson; Kai Zheng
Journal:  J Am Med Inform Assoc       Date:  2015-08-11       Impact factor: 4.497

3.  Clinical Trial Assessment of Infrastructure Matrix Tool to Improve the Quality of Research Conduct in the Community.

Authors:  Eileen P Dimond; Robin T Zon; Bryan J Weiner; Diane St Germain; Andrea M Denicoff; Kandie Dempsey; Angela C Carrigan; Randall W Teal; Marjorie J Good; Worta McCaskill-Stevens; Stephen S Grubbs; Eileen P Dimond; Robin T Zon; Bryan J Weiner; Diane St Germain; Andrea M Denicoff; Kandie Dempsey; Angela C Carrigan; Randall W Teal; Marjorie J Good; Worta McCaskill-Stevens; Stephen S Grubbs
Journal:  J Oncol Pract       Date:  2015-12-01       Impact factor: 3.840

Review 4.  Barriers to accrual and enrollment in brain tumor trials.

Authors:  Eudocia Q Lee; Ugonma N Chukwueke; Shawn L Hervey-Jumper; John F de Groot; Jose Pablo Leone; Terri S Armstrong; Susan M Chang; David Arons; Kathy Oliver; Kay Verble; Al Musella; Nicole Willmarth; Brian M Alexander; Amanda Bates; Lisa Doherty; Evanthia Galanis; Sarah Gaffey; Thomas Halkin; Bret E Friday; Maryam Fouladi; Nancy U Lin; David Macdonald; Minesh P Mehta; Marta Penas-Prado; Michael A Vogelbaum; Solmaz Sahebjam; David Sandak; Martin van den Bent; Michael Weller; David A Reardon; Patrick Y Wen
Journal:  Neuro Oncol       Date:  2019-09-06       Impact factor: 12.300

5.  Motivators and barriers to Latinas' participation in clinical trials: the role of contextual factors.

Authors:  Laricca London; Alejandra Hurtado-de-Mendoza; Minna Song; Ankita Nagirimadugu; Gheorghe Luta; Vanessa B Sheppard
Journal:  Contemp Clin Trials       Date:  2014-11-26       Impact factor: 2.226

6.  Disparities in castration-resistant prostate cancer trials.

Authors:  Daniel E Spratt; Joseph R Osborne
Journal:  J Clin Oncol       Date:  2015-02-17       Impact factor: 44.544

7.  The Role of Clinical Trial Participation in Cancer Research: Barriers, Evidence, and Strategies.

Authors:  Joseph M Unger; Elise Cook; Eric Tai; Archie Bleyer
Journal:  Am Soc Clin Oncol Educ Book       Date:  2016

8.  Premature Clinical Trial Discontinuation in the Era of Immune Checkpoint Inhibitors.

Authors:  Monica Khunger; Sagar Rakshit; Adrian V Hernandez; Vinay Pasupuleti; Kate Glass; Matthew D Galsky; Petros Grivas
Journal:  Oncologist       Date:  2018-08-01

Review 9.  Project PLACE: Enhancing community and academic partnerships to describe and address health disparities.

Authors:  Nadine J Barrett; Kearston L Ingraham; Kenisha Bethea; Pao Hwa-Lin; Maritza Chirinos; Laura J Fish; Schenita Randolph; Ping Zhang; Peter Le; Demetrius Harvey; Ronald L Godbee; Steven R Patierno
Journal:  Adv Cancer Res       Date:  2020-03-19       Impact factor: 6.242

10.  Willingness to Participate in Cardiovascular Clinical Research among African-Americans.

Authors:  P Stuchlik; X Zhang; S Gavin; S Gaudreau; J L Breault; L A Bazzano
Journal:  J Clin Res Bioeth       Date:  2015-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.